RESUMO
Cutaneous melanoma has always been a dreaded diagnosis because of its high mortality rate and its proclivity for invasiveness and metastasis. Historically, advanced melanoma treatment has been limited to chemotherapy and nonspecific immunotherapy agents that display poor curative potential and high toxicity. However, during the last decade, the evolving understanding of the mutational burden of melanoma and immune system evasion mechanisms has led to the development of targeted therapy and specific immunotherapy agents that have transformed the landscape of advanced melanoma treatment. Despite the considerable strides in understanding the clinical implications of these agents, there is a scarcity of randomized clinical trials that directly compare the efficacy of the aforementioned agents; hence, there are no clear preferences among the available first-line options. In addition, the introduction of these agents was associated with a variety of dermatologic adverse events, some of which have shown a detrimental effect on the continuity of treatment. This holds especially true in light of the current fragmentation of care provided by the managing health care professionals. In this study, we attempt to summarize the current understanding of first-line treatments. In addition, the paper describes the indirect comparative evidence that aids in bridging the gap in the literature. Furthermore, this paper sheds light on the impact of the scarcity of dermatology specialist input in the management of dermatologic adverse events associated with advanced melanoma treatment. It also looks into the potential avenues where dermatologic input can bridge the gap in the care provided by oncologists, thus standardizing the care provided to patients with melanoma presenting with dermatologic adverse events.
Assuntos
Crioterapia , Ácido Salicílico/uso terapêutico , Verrugas/terapia , Feminino , Humanos , MasculinoRESUMO
Mostly, herpes zoster affects adults and therefore childhood presentation can represent a diagnostic challenge. Childhood herpes zoster, when it occurs, can also be associated with peripheral nerve complications, as illustrated by this case. A 3-year-old child who had herpes zoster developed a nasolabial scar resulting in a shallow non-healing ulcer from being repeatedly picked. Healing was only achieved after nocturnal sedation, with chloral hydrate.
Assuntos
Hidrato de Cloral/uso terapêutico , Dor Facial/tratamento farmacológico , Herpes Zoster/tratamento farmacológico , Hipnóticos e Sedativos/uso terapêutico , Úlcera/tratamento farmacológico , Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Pré-Escolar , Face/virologia , Dor Facial/etiologia , Feminino , Herpes Zoster/complicações , Herpes Zoster/diagnóstico , Humanos , Úlcera/virologiaRESUMO
BACKGROUND: We conducted a double-blind, placebo-controlled, randomized trial to evaluate the preliminary efficacy and safety of imiquimod 5% cream treatment for cutaneous squamous cell carcinoma (SCC) in situ. METHODS: In all, 31 patients with biopsy-proven cutaneous SCC in situ were randomly assigned to placebo (vehicle) (n = 16) or imiquimod 5% cream (n = 15) daily for 16 weeks. Patients were assessed at week 28 for the primary end point, resolution of cutaneous SCC in situ. RESULTS: Of the 31 patients enrolled, 3 dropped out. Intention-to-treat analysis revealed 11 of the 15 patients (73%) in the imiquimod group achieved resolution of cutaneous SCC in situ, with no relapse during the 9-month follow-up period; none in the placebo group achieved resolution (P < .001). Imiquimod 5% cream was generally well tolerated and there were no serious adverse events. LIMITATIONS: Topical imiquimod 5% cream has proven to be an effective treatment for cutaneous SCC in situ. However, studies to define the ideal dosing regimen and cost-effectiveness are required before it can be accepted as a recognized therapy. CONCLUSIONS: In this controlled trial, patients with cutaneous SCC in situ receiving topical imiquimod 5% cream as monotherapy experienced a high degree of clinical benefit compared with placebo.
Assuntos
Aminoquinolinas/administração & dosagem , Antineoplásicos/administração & dosagem , Doença de Bowen/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Idoso , Idoso de 80 Anos ou mais , Formas de Dosagem , Método Duplo-Cego , Feminino , Humanos , Imiquimode , Masculino , Pessoa de Meia-IdadeRESUMO
BACKGROUND: Bipolar diathermy coagulates tissue as effectively as monopolar with less lateral tissue injury and no risk of interference with cardiac pacemakers or joint prostheses. OBJECTIVE: To test a novel computerized bipolar diathermy machine for combined cutting and coagulation in dermatologic surgery. METHODS: A divided cable was used to deliver current from a computerized bipolar diathermy unit to both scissors and forceps. The bipolar diathermy unit senses tissue contact with the instruments and starts automatically; a built-in microcomputer measures tissue impedance and automatically terminates the current when tissue coagulation is achieved. RESULTS: The equipment has been used successfully in more than 200 patients undergoing dermatologic surgery. The advantages were a reduced operating time and a more secure hemostasis. The microprocessor controlled bipolar diathermy unit minimized any tissue adherence to the instruments during use. CONCLUSION: We recommend the use of insulated scissors and computerized bipolar diathermy for safe and efficacious coagulation and cutting in dermatologic surgery.